Anadis Partners with Garden State Nutritionals (GSN) for US Market Entry
of Its Milk-Derived (Colostrum) Bioactive Products
MELBOURNE, Australia (Business Wire EON/PRWEB ) March 16, 2008 --
Anadis (ASX:ANX) (OTC:ANDIY), an Australian Biopharmaceutical company
announced today its collaboration with Garden State Nutritionals, a New
Jersey based division (GSN) of VitaQuest International in the field of
dietary supplements. Anadis and GSN plans to introduce in the coming
months and years a range of products, all based on Anadis’
proprietary and all-natural milk-derived (colostrum) bioactives and
immunoglobulins. The collaboration will allow Anadis to further expedite
its penetration into the U.S. Vitamins and dietary supplements, a market
which exceeds $15Bn in size, and which experiences growth rate in excess
of 5% (Market research/Euro Monitor, 2007).
GSN is one of the largest custom contract manufacturers of nutritional
supplements in the United States, and is a leading producer of more than
$1 billion in finished retail products per year. With advanced 250,000
sq. ft. manufacturing and packaging facility they produce more than 500
million doses per month and reach all geographical areas of the United
States as well as supply to all major regional and national nutritional
commercial channels.
“Our expert and dedicated management team has
an impressive average of more than 25 years of broad industry
experience. We are thrilled to have Anadis with its proprietary
Colostrum derived bioactives working with us. We see great potential in
introducing Anadis to our more than 300 clients,“
said Jon Weisgal, VP of Marketing, VitaQuest.
Dr. Zeil Rosenberg, Anadis’ New York
City-based CEO, said: “GSN develops and
manufacture cost-effective, market-leading dietary supplements products
in every distribution channel, including health and natural food stores,
mass merchandisers, network marketing and direct selling, television
shopping, drug chain and direct response TV and radio.”
Dr. Oren Fuerst, Anadis’ New York City-based
VP Business Development said: “Collaboration
with GSN allows Anadis to offer our marketing partners complete turnkey
solutions, including product concepts, formulations, laboratory
services, package and label design, regulatory compliance and assistance
in marketing and merchandising. The combination of GSN’s
skills with our decade of R&D in the field of dairy-derived colostrum
bioactives will now allow Anadis to rapidly penetrate the U.S. vitamins
and dietary supplements market. This is a four way win combination to
Anadis, GSN, the dietary supplements brands under which these products
will be marketed, and above all consumers, who will be offered a broad
range of new products based on our proprietary, all-natural colostrum
platform."
About GSN:
GSN is one of the largest custom contract manufacturers of nutritional
supplements in the United States. GSN has a highly skilled Product
Development group, as well as a Scientific Advisory Board to help avail
clients of the latest developments and technical innovations. This
multidisciplinary team includes leading research scientists, molecular
biologists, physicians, pharmacists, clinical nutritionists, herbalists,
food technologists, and sports physiologists.
GSN’s facilities are FDA-inspected and operate
under strict Good Manufacturing Practices (GMP), and have earned the
coveted NNFA GMP "A" Rating. GSN’s
kosher-approved facilities have been audited and approved by leading
independent bodies.
GSN supplies dietary supplements to more than 35 countries around the
world. Its Regulatory Affairs group works with customers and regional
health authorities to ensure compliance in documentation requirements
for each country.
About Anadis (www.anadis.com):
Anadis Limited (ASX:ANX) (OTC:ANDIY) is a biopharmaceutical company
producing antibodies and other bioactive proteins as health products.
Its all-natural, orally administered and colostrum-derived platform is
proven safe and effective, with regulatory classification as GRAS
(Generally Regarded as Safe) and BSE-free certification, allowing for
rapid progression from concept to market. The company’s
core technology relies on advanced dairy industry processing methods
including immunization of pregnant cows with proprietary antigen
specific vaccines, which in turn elicit an immune response by the cow.
First-milking colostrum contains more than 35% immunoglobulin and this
targeted antibody, along with other immune system bioactive nutrients,
is subsequently harvested, fractionated and freeze dried under the
highest dairy industry standards. The company is addressing a variety of
unmet human health needs with broad market demand, including: Oral and
GI Mucositis; Inflammatory Bowel Disease (IBD); Irritable Bowel Syndrome
(IBS); Travellers’ Diarrhea; Influenza,
Clostridium Difficile and Rotavirus. The company operates from
Melbourne, Australia and New York City.
See the original story at: http://eon.businesswire.com/releases/anadis/state/prweb777184.htm
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/RW1wdC1DcmFzLUhvcnItRmFsdS1Ib3JyLVplcm8=
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
